Zolodrenic acid can prevent early bone loss in HIV patients on antiretroviral therapy

(Emory Health Sciences) A single dose of the drug zoledronic acid was found to inhibit the bone loss that is common in HIV-infected patients and that is increased during the first two years of treatment with antiretroviral therapy. Bone loss also leads to a higher rate of fracture in HIV-infected individuals.
Source: EurekAlert! - Medicine and Health - Category: Global & Universal Source Type: news